AREC vs. TRX, SAR, ETX, C4XD, REDX, OBD, HEMO, OBI, ONC, and OPTI
Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Tissue Regenix Group (TRX), Sareum (SAR), e-therapeutics (ETX), C4X Discovery (C4XD), Redx Pharma (REDX), Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), Ondine Biomedical (OBI), Oncimmune (ONC), and OptiBiotix Health (OPTI). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics (LON:AREC) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Tissue Regenix Group received 162 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
Tissue Regenix Group has a net margin of -5.81% compared to Arecor Therapeutics' net margin of -278.81%. Tissue Regenix Group's return on equity of -5.55% beat Arecor Therapeutics' return on equity.
In the previous week, Arecor Therapeutics had 1 more articles in the media than Tissue Regenix Group. MarketBeat recorded 1 mentions for Arecor Therapeutics and 0 mentions for Tissue Regenix Group. Arecor Therapeutics' average media sentiment score of 0.14 beat Tissue Regenix Group's score of 0.00 indicating that Arecor Therapeutics is being referred to more favorably in the media.
Tissue Regenix Group has higher revenue and earnings than Arecor Therapeutics. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.
54.2% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Tissue Regenix Group shares are owned by institutional investors. 31.3% of Arecor Therapeutics shares are owned by company insiders. Comparatively, 46.8% of Tissue Regenix Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Arecor Therapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Summary
Tissue Regenix Group beats Arecor Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Arecor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arecor Therapeutics Competitors List
Related Companies and Tools
